Phase 2 Mesothelioma Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People diagnosed with advanced clear cell renal cell carcinoma (a type of kidney cancer), osteosarcoma (a type of bone cancer), or mesothelioma (a cancer linked to the lining of the lungs or other organs), where a tumour sample shows a specific protein called CD70 at certain levels (confirmed by lab testing).
• People whose cancer meets additional disease-specific requirements depending on which cancer type they have (see details below, and confirm specifics with the trial site).
• People who have waited at least 2 weeks since their last chemotherapy, targeted therapy, or similar cancer treatment before starting the trial's preparatory treatment.
• People who have waited at least 3 months since any previous cell-based cancer therapy.
• People who may have had radiation to one or more tumour sites beforehand, as long as there are still other measurable tumours that were not irradiated.
• People who are generally well enough to carry out daily activities, rated at a good functional level on a standard medical scale (ECOG performance status 0 or 1, or equivalent scale for those aged 16 or under).
• People whose kidneys, liver, heart, lungs, and blood counts are all functioning within acceptable ranges at screening (specific lab values will be checked by the trial team).
• People aged 16 to 80 years.
• People who weigh at least 40 kg.
• People who are able to use effective contraception during the trial and for up to 3 months afterwards, or who are not able to have children.
• People who are not pregnant at the time of screening (confirmed by a pregnancy test, where applicable).
• People who are able to provide written consent to participate, including a separate agreement for long-term follow-up.

Disease-specific criteria (confirm details with trial site):

• Kidney cancer (clear cell renal cell carcinoma): People with Stage 4 kidney cancer who have already received at least one prior treatment including both an immunotherapy (PD-1/PD-L1 type) and an anti-cancer targeted therapy, and who have at least one measurable tumour site of more than 10 mm on a CT scan.
• Mesothelioma: People with confirmed mesothelioma whose cancer has progressed or come back after all standard treatments including chemotherapy, targeted therapy, and radiotherapy, and who have measurable or assessable disease.
• Osteosarcoma: People with confirmed osteosarcoma that has come back or stopped responding to standard treatments, who have received at least one chemotherapy regimen of a specific drug class (anthracyclines) if there was no medical reason to avoid it, and who have measurable or assessable disease confirmed by imaging.

Who may not be able to join:

• People who still have significant ongoing side effects (Grade 2 or higher) from previous cancer treatments that have not improved to a mild level.
• People with an active infection that requires intravenous antibiotics or is not responding to treatment (simple urinary tract infections or uncomplicated throat infections that are responding to treatment may be acceptable — confirm with trial site).
• People with known active hepatitis B or hepatitis C infection.
• People with HIV who have a detectable amount of virus in their blood (those with undetectable levels may also be excluded in certain circumstances depending on their HIV medications — confirm with trial site).
• People with an active neurological condition.
• People who have had an active autoimmune disease within the past 12 months (mild psoriasis or well-controlled thyroid disease may be acceptable — confirm with trial site).
• People with a condition called amyloidosis or POEMS syndrome.
• People with cancer that has spread to the brain or spinal cord in a way that is causing symptoms or is not controlled.
• People who have been diagnosed with another cancer in the past 2 years, with some exceptions for certain low-risk or fully treated cancers (confirm specifics with trial site).
• People with serious heart conditions, including severe heart failure, a heart attack or stroke within approximately 6 months, unstable chest pain within approximately 3 months, severe aortic valve disease, uncontrolled heart rhythm problems, a condition called congenital long QT syndrome, or an abnormal heart electrical reading at screening.
• People who have had major surgery within 4 weeks before starting the trial's preparatory treatment.
• People who are currently taking part in another clinical trial using an investigational treatment.
• People who are currently receiving other anti-cancer treatments.
• People who have previously received any treatment that targets the CD70 protein.
• People who are taking systemic steroid medications above a low dose threshold (certain inhaled, nasal, eye, or skin-applied steroids, and very low-dose oral steroids, may be acceptable — confirm with trial site).
• People who have received certain immune-suppressing medications (antithymocyte globulin or Campath) within a recent specified period before enrolment.
• People who are currently receiving any other immunosuppressive therapy.
• People who are pregnant or breastfeeding.

Important: Always verify eligibility with the trial site directly before applying.